PepGen announces excellent results from the low-dose (5 mg/kg) MAD cohort in the ongoing phase FREEDOM2 study, showing favorable safety, efficacy and vHOT data.
– PGN-EDODM1 was generally well tolerated with all adverse events being mild or moderate and no serious adverse events reported – – Dissociation correction observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); 7.3%; With the exception of one outpatient, the treatment group showed a mean improvement of 22.9% (n = 5). – A significant … Read more